Tag Archives: Catabasis Pharmaceuticals

June, 2018

27 June
Catabasis Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in DMD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add …
Share

8 June
New Data Supports Potential of Catabasis’ CAT-5571 as Novel Oral Treatment for Cystic Fibrosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announces positive preclinical data on CAT-5571, supporting its potential as an oral treatment for cystic fibrosis (CF). These data are being presented today at the 40th Annual European Cystic Fibrosis Society (ECFS) Conference in Seville, Spain. Patients with CF suffer …
Share

1 February
Catabasis’ Investigational Duchenne Muscular Dystrophy Drug Fails Mid-Stage Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2017– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line safety and efficacy results for Part B of the MoveDMD® trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD). The objective of Part B of the MoveDMD trial was to evaluate …
Share

5 February
Catabasis Teams up with Muscular Dystrophy Association on New Disease-Modifying Treatment for DMD

CAMBRIDGE, Mass. & CHICAGO–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, and the Muscular Dystrophy Association (MDA), today announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment …
Share

25 January
Catabasis Announces Positive Top-Line Results from its Duchenne Muscular Dystrophy Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced positive top-line results from Part A of the MoveDMD trial, a Phase 1 / 2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD or Duchenne). All …
Share